Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Complications of Diabetes Mellitus01:22

Complications of Diabetes Mellitus

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, resistance, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and leads to acute and chronic complications.Acute ComplicationsAcute complications result from sudden metabolic imbalance.Diabetic ketoacidosis (DKA) mainly appears in type 1 diabetes but may also develop in type 2 diabetes, particularly under extreme stress. It arises from severe insulin deficiency,...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in the prevalence of cardiovascular disease, defined as ECG abnormalities and/or self-reported events, in Mauritius between 1987 and 2021: analysis of data from seven large population-based surveys.

BMJ open·2025
Same author

Prevalence and risk factors of hypertension in Mauritius: A cross-sectional study.

PLOS global public health·2024
Same author

Translation of culturally and contextually informed diabetes training for Aboriginal primary health care providers on Aboriginal client outcomes: Protocol of a cluster randomized crossover trial of effectiveness.

PloS one·2024
Same author

Prevalence and social determinants of smoking among men in Mauritius: a cross-sectional study.

Global health action·2024
Same author

The circadian syndrome is a predictor for cognition impairment in middle-aged adults: Comparison with the metabolic syndrome.

Diabetes/metabolism research and reviews·2024
Same author

Supporting best practice in the management of chronic diseases in primary health care settings: a scoping review of training programs for Indigenous Health Workers and Practitioners.

Australian journal of primary health·2024

Related Experiment Video

Updated: Jun 24, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Preventing diabetic complications: a primary care perspective.

Paul Zimmet1

  • 1Baker IDI Heart and Diabetes Institute, 250 Kooyong Road, Caulfield, Victoria 3162, Australia. Paul.Zimmet@bakeridi.edu.au

Diabetes Research and Clinical Practice
|March 13, 2009
PubMed
Summary

Fenofibrate significantly reduced cardiovascular events and microvascular complications in diabetes patients, particularly those with abnormal lipid profiles. This suggests fenofibrate is a valuable option for managing diabetic vascular complications.

More Related Videos

Effects of Mindfulness Training Combined with Tai Chi in Patients with Diabetic Peripheral Neuropathy
05:06

Effects of Mindfulness Training Combined with Tai Chi in Patients with Diabetic Peripheral Neuropathy

Published on: July 14, 2023

Related Experiment Videos

Last Updated: Jun 24, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Effects of Mindfulness Training Combined with Tai Chi in Patients with Diabetic Peripheral Neuropathy
05:06

Effects of Mindfulness Training Combined with Tai Chi in Patients with Diabetic Peripheral Neuropathy

Published on: July 14, 2023

Area of Science:

  • Cardiology
  • Endocrinology
  • Diabetology

Background:

  • Cardiometabolic risk factor control is key in diabetes management.
  • Despite intensive treatment of glucose, blood pressure, and lipids, significant disease burden persists.
  • The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study offers new insights.

Purpose of the Study:

  • To evaluate the effects of fenofibrate on cardiovascular and microvascular outcomes in patients with diabetes.
  • To assess fenofibrate's role in managing diabetic vascular complications.

Main Methods:

  • Analysis of data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
  • Evaluation of cardiovascular events and microvascular outcomes in participants treated with fenofibrate.

Main Results:

  • Fenofibrate significantly reduced total cardiovascular disease events.
  • A notable reduction in events was observed in patients with atherogenic dyslipidemia (low HDL, high triglycerides).
  • Fenofibrate demonstrated preventive effects on microvascular outcomes, including retinopathy, albuminuria progression, and amputations.

Conclusions:

  • Fenofibrate effectively reduces cardiovascular events in diabetic patients, especially those with dyslipidemia.
  • Fenofibrate shows significant benefits in preventing microvascular complications associated with diabetes.
  • Re-evaluation of fenofibrate is warranted as a therapeutic option for reducing diabetic vascular complications.